expense and related tax benefits of:
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Cost of products and services
sold $(7,137) $(8,537) $(25,677) $(21,430)
Selling, general and
administrative (23,334) (25,262) (106,172) (121,822)
Research and development (13,128) (14,566) (58,101) (65,248)
Total pre-tax charges for
stock-based compensation
expense (43,599) (48,365) (189,950) (208,500)
Tax benefit 12,920 14,094 58,148 66,331
Stock-based compensation
expense, net of tax $(30,679) $(34,271) $(131,802) $(142,169)
Diluted earnings per share and diluted weighted average shares outstanding
for the three months and years ended December 31, 2007 and 2006 were
computed according to the provisions of FAS 123R.
(2) Includes charges of $(9,143)K recorded in December 2007 to write off
five finished lots of our Thymoglobulin inventory which did not meet
our specifications and $(11,773)K recorded in September 2007 to write
off four finished lots of our Thymoglobulin inventory which did not
meet our specifications.
(3) Includes a charge of $(64,000)K recorded in June 2007 to settle the
litigation related to the consolidation of our former tracking
stocks.
(4) Includes a charge of $(25,000)K for an upfront milestone payment paid
to Ceregene Inc. in June 2007 for the development and
commercialization of certain gene therapy products.
(5) Includes charges for the purchase of in-process research and
development of $(106,350)K related to our
'/>"/>
| SOURCE Genzyme Corporation Copyright©2008 PR Newswire. All rights reserved |